Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Denmark Introduces Early Dialogue With Procurement Agency For Expensive Medicines

Executive Summary

Earlier dialogues would mean faster access to new medicines.

You may also be interested in...



English & Scottish HTAs Diverge On Sanofi’s Dupixent For Rare Skin Condition

The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.

BMS Secures Better HTA Result In Germany With Additional Data for Camzyos

A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.

Mexico Launches ‘Regulatory Certainty Strategy’ For Biosimilars

Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel